Searched for
SANDOZ BUSINESS
ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...- Dr Reddy’s shares fall 2% after Goldman Sachs downgrades, Citi turns cautiousDr Reddy’s shares fell after Goldman Sachs and Citigroup turned cautious, citing limited growth visibility, pipeline concerns and valuation...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Strides Pharma to acquire Sandoz branded generics portfolio to expand Africa businessStrides Pharma Science is preparing to enhance its presence in Sub-Saharan Africa by acquiring branded generic products from Sandoz AG, wit...
- Novartis to spin off generics biz sandozThe company started a strategic review of Sandoz last October - examining a range of options, including retaining the business, spinning it...
- Swiss drugmaker Novartis to spin off generics unit SandozThe Basel-based company, which makes a vast array of drugs including cancer treatment Gleevec and Diovan for hypertension, says it wants to...
- Novartis opens new manufacturing plant in Mumbai to make generic cancer drugsSpread across 32,000 sqm, and housing state-of-the-art production technology, the plant is built to cater to export markets. It currently h...
- Buy Aurobindo Pharma, target price Rs 485: ICICI SecuritiesTaking Sandoz out of estimates, the brokerage now expects consolidated revenue growth in mid-single digit for Aurobindo over the next two y...
- Brokerages lower Aurobindo Pharma target price by 17-27%Brokerages see the termination of the deal as a setback to scale up sales in the US .
- Buy Aurobindo Pharma, target price Rs 450: Motilal OswalThe brokerage has reduced its earnings estimate for FY21/FY22 by 19 per cent/18 per cent to Rs 51/Rs 53 to factor in termination of Sandoz ...
- US concerns on key drugs wreck Aurobindo’s plan to buy Sandoz bizThe FTC was not convinced on several issues pertaining to continued availability of these critical drugs and didn’t accept the alternatives...
- Aurobindo, Sandoz call off USD 900 mn dealThe transaction if completed would have positioned the Hyderabad-based firm as the second largest dermatology player and the second largest...
- Novartis scraps sale of assets including COVID-19 hopeful to India's AurobindoNovartis AG on Thursday scrapped the $1 billion sale of U.S. generic pill and skin drug assets to India's Aurobindo Pharma Ltd as regulator...
- Aurobindo Pharma aims to become debt free in 3 years sans Sandoz dealIn September last year, the USD three billion drug maker said its US subsidiary entered into an agreement to acquire commercial operations ...
- Aurobindo’s buyout of Sandoz assets delayed on FTC queryOn Wednesday, shares of Aurobindo closed 4.8 per cent lower at Rs 450.75 on the BSE.
- Aurobindo Pharma lines up $200 million capex for FY20Aurobindo Pharma Ltd. to invest $ 200 million on Capex and over 5% of sale value on R&D.
- Buy Aurobindo Pharma, target Rs 836: Elara CapitalBuy Aurobindo Pharma Ltd. at a price target of Rs 836.
- Aurobindo buys US units of Sandoz for $900 millionThe acquired business has been carved out by the management of Sandoz for divestment.
- Aurobindo Pharma acquires dermatology business from Sandoz in a $900 million cash dealThe acquisition will add approximately 300 products including projects in development as well as commercial and manufacturing capabilities ...
- Novartis India appoints Milan Paleja as vice chairman and MDPaleja is currently country president at Novartis in India and is also responsible for the pharmaceuticals business in the country. He is a...
Load More
